KR20240026999A - 클로스트리듐ㆍ디피실균에 결합하는 항체 - Google Patents

클로스트리듐ㆍ디피실균에 결합하는 항체 Download PDF

Info

Publication number
KR20240026999A
KR20240026999A KR1020247001366A KR20247001366A KR20240026999A KR 20240026999 A KR20240026999 A KR 20240026999A KR 1020247001366 A KR1020247001366 A KR 1020247001366A KR 20247001366 A KR20247001366 A KR 20247001366A KR 20240026999 A KR20240026999 A KR 20240026999A
Authority
KR
South Korea
Prior art keywords
amino acid
acid sequence
ser
thr
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247001366A
Other languages
English (en)
Korean (ko)
Inventor
레이코 신쿠라
토모유키 모리
류타로 타마노
나오시 도마에
토시오 하코시마
Original Assignee
고쿠리츠다이가쿠호우진 도쿄다이가쿠
고쿠리츠다이가쿠호징 나라 센탄카가쿠기쥬츠 다이가쿠인 다이가쿠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 고쿠리츠다이가쿠호우진 도쿄다이가쿠, 고쿠리츠다이가쿠호징 나라 센탄카가쿠기쥬츠 다이가쿠인 다이가쿠 filed Critical 고쿠리츠다이가쿠호우진 도쿄다이가쿠
Publication of KR20240026999A publication Critical patent/KR20240026999A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020247001366A 2021-07-01 2022-06-30 클로스트리듐ㆍ디피실균에 결합하는 항체 Pending KR20240026999A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021110421 2021-07-01
JPJP-P-2021-110421 2021-07-01
PCT/JP2022/026277 WO2023277142A1 (ja) 2021-07-01 2022-06-30 クロストリジウム・ディフィシル菌に結合する抗体

Publications (1)

Publication Number Publication Date
KR20240026999A true KR20240026999A (ko) 2024-02-29

Family

ID=84692781

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247001366A Pending KR20240026999A (ko) 2021-07-01 2022-06-30 클로스트리듐ㆍ디피실균에 결합하는 항체

Country Status (9)

Country Link
US (1) US20250188157A1 (https=)
EP (1) EP4365293A4 (https=)
JP (3) JP7425452B2 (https=)
KR (1) KR20240026999A (https=)
CN (1) CN117716035A (https=)
AU (1) AU2022305377A1 (https=)
CA (1) CA3224497A1 (https=)
TW (1) TW202317611A (https=)
WO (1) WO2023277142A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202440928A (zh) 2023-03-03 2024-10-16 國立大學法人東京大學 免疫球蛋白
CN121127591A (zh) 2023-05-12 2025-12-12 国立大学法人东京大学 与艰难梭菌结合的抗体
WO2025134928A1 (ja) * 2023-12-21 2025-06-26 国立大学法人 東京大学 結腸直腸がんを治療するための組成物
WO2025220732A1 (ja) * 2024-04-17 2025-10-23 国立研究開発法人国立循環器病研究センター 肺高血圧症の予防又は治療薬
WO2025225737A1 (ja) * 2024-04-26 2025-10-30 国立大学法人 東京大学 微生物と抗体の組み合わせおよび使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030003104A1 (en) * 2001-07-02 2003-01-02 John Mottola Method for removal of pathogens from a localized environment
JP5916946B2 (ja) * 2013-03-11 2016-05-11 学校法人関西文理総合学園 モノクローナルＩｇＡ抗体の製造方法
JP2017001987A (ja) * 2015-06-11 2017-01-05 学校法人関西文理総合学園 ポリペプチド

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Bry L, et al., Science 1996; 273：1380
Cerf-Bensussan N, and Gaboriau-Routhiau V., Nat Rev Immunol 2010; 10：735
Hooper LV, and Macpherson AJ., Nat Rev Immunol 2010; 10：159
Round JL, and Mazmanian SK, Proc Natl Acad Sci USA 2010; 107：12204
Shulzhenko N, et al., Nat Med 2011; 17：1585
Turnbaugh PJ, et al., Nature 2006; 444：1027
Vijay-Kumar M, et al., Science 2010; 328：228

Also Published As

Publication number Publication date
AU2022305377A1 (en) 2024-02-15
JP2023123746A (ja) 2023-09-05
EP4365293A4 (en) 2026-03-11
CA3224497A1 (en) 2023-01-05
JPWO2023277142A1 (https=) 2023-01-05
TW202317611A (zh) 2023-05-01
US20250188157A1 (en) 2025-06-12
JP2024041901A (ja) 2024-03-27
JP7405386B2 (ja) 2023-12-26
EP4365293A1 (en) 2024-05-08
JP7425452B2 (ja) 2024-01-31
CN117716035A (zh) 2024-03-15
WO2023277142A1 (ja) 2023-01-05

Similar Documents

Publication Publication Date Title
KR20240026999A (ko) 클로스트리듐ㆍ디피실균에 결합하는 항체
KR20240026998A (ko) 클로스트리듐ㆍ디피실균의 증식을 억제하기 위한 모노클로날 항체 함유 조성물
CN109790218B (zh) 抗tim-3抗体及其用途
KR101683033B1 (ko) 톨-유사 수용체 3 길항제
US9765151B2 (en) Method for producing monoclonal IgA antibody
KR101758713B1 (ko) 톨-유사 수용체 3 길항제
CN114366818A (zh) 抗体药物偶联物及其应用
KR20140075708A (ko) 대사 및 심혈관 질환의 치료를 위한 톨-유사 수용체 3 길항제
CN114040924B (zh) 对lif具有特异性的结合分子及其用途
US20250051426A1 (en) Composition containing monoclonal antibody
RU2829997C1 (ru) Антитело к cldn-18.2 и его применение
RU2732155C1 (ru) Гуманизированное антитело или его антигенсвязывающий фрагмент (Fab) против шига-токсинов первого и/или второго типов (варианты), композиция для лечения токсических состояний, вызванных энтерогеморрагической кишечной палочкой, содержащая указанные антитела и/или Fab
WO2024237217A1 (ja) クロストリジオイデス・ディフィシル菌に結合する抗体

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240112

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250416

Comment text: Request for Examination of Application